Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed, Refractory Multiple Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT07589634
What this trial is testing

A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 230
Not applicableLooking for participantsNCT07559799
What this trial is testing

A Non-interventional Study of Melphalan Flufenamide (Melflufen) (Pepaxti®) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (R/RMM)

Who this might be right for
Multiple Myeloma
iOMEDICO AG 50
Testing effectiveness (Phase 2)Study completedNCT02834364
What this trial is testing

BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)

Who this might be right for
Relapsed or Refractory Multiple MyelomaPatients With BRAFV600 E or BRAFV600K Mutation
University of Heidelberg Medical Center 12
Early research (Phase 1)Study completedNCT01758328
What this trial is testing

Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Memorial Sloan Kettering Cancer Center 29
Early research (Phase 1)Active Not RecruitingNCT05646836
What this trial is testing

Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Genentech, Inc. 90
Very early researchUnknownNCT04637269
What this trial is testing

Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma

Who this might be right for
Multiple Myeloma
Xinqiao Hospital of Chongqing 16
Testing effectiveness (Phase 2)Study completedNCT03184194
What this trial is testing

Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide

Who this might be right for
Myeloma
Amsterdam UMC, location VUmc 62
Not applicableActive Not RecruitingNCT06479954
What this trial is testing

Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.

Who this might be right for
Relapsed and Refractory Multiple Myeloma (RRMM)
Pfizer 1
Early research (Phase 1)Ended earlyNCT03465540
What this trial is testing

Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

Who this might be right for
Multiple MyelomaAcute Myeloid LeukemiaNon-Hodgkins Lymphoma+4 more
Amgen 24
Testing effectiveness (Phase 2)Study completedNCT01450215
What this trial is testing

Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide in Second Line Multiple Myeloma

Who this might be right for
Multiple Myeloma
Karolinska University Hospital 62
Early research (Phase 1)UnknownNCT04601935
What this trial is testing

A Single-center Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of a BCMA-targeted Universal LCAR-BCX Cells in Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma
Weijun Fu 34
Testing effectiveness (Phase 2)UnknownNCT03322735
What this trial is testing

Study of BCMA CAR-T in Multiple Myeloma

Who this might be right for
Multiple Myeloma
Henan Cancer Hospital 10
Testing effectiveness (Phase 2)Study completedNCT03170882
What this trial is testing

Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma
Millennium Pharmaceuticals, Inc. 122
Testing effectiveness (Phase 2)Looking for participantsNCT06988488
What this trial is testing

Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 62
Testing effectiveness (Phase 2)Active Not RecruitingNCT04094961
What this trial is testing

Ixazomib + Pomalidomide + Dexamethasone In MM

Who this might be right for
Multiple MyelomaMultiple Myeloma in Relapse
Omar Nadeem, MD 52
Early research (Phase 1)Not Yet RecruitingNCT07407010
What this trial is testing

BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM

Who this might be right for
Relapsed Refractory Multiple Myeloma (RRMM)
Institute of Hematology & Blood Diseases Hospital, China 10
Testing effectiveness (Phase 2)UnknownNCT03767751
What this trial is testing

A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Chinese PLA General Hospital 80
Testing effectiveness (Phase 2)UnknownNCT01522872
What this trial is testing

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Threshold Pharmaceuticals 98
Testing effectiveness (Phase 2)UnknownNCT05066646
What this trial is testing

A Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)

Who this might be right for
Multiple Myeloma
Nanjing IASO Biotechnology Co., Ltd. 132
Testing effectiveness (Phase 2)Study completedNCT02056756
What this trial is testing

Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Stichting European Myeloma Network 63
Next Page